Mogroside V

SKU: orb1304779

Description

Mogroside V is a natural sweetener with demonstrated AMPK-activating, antioxidant, and anti-inflammatory properties in vitro. Research indicates its potential in models of acute lung injury (ALI), ear edema, and pancreatic cancer, highlighting applications in metabolic, inflammatory, and oncology studies.

Research Area

Epigenetics & Chromatin, Immunology & Inflammation, Metabolism Research, Signal Transduction

Key Properties

• CAS Number: 88901-36-4
• MW: 1287.43
• Purity: 99.86% (May vary between batches)
• Formula: C₆₀H₁₀₂O₂₉
• SMILES: C[C@H](CC[C@@H](O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)(C)O)[C@H]1CC[C@@]2(C)[C@@H]3CC=C4[C@@H](CC[C@H](O[C@@H]5O[C@H](CO[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)[C@@H](O)[C@H](O)[C@H]5O)C4(C)C)[C@]3(C)[C@H](O)C[C@]12C
• Target: AMPK,ROS,Reactive Oxygen Species
• Solubility: H2O:100 mg/mL (77.67 mM);Ethanol:Soluble;DMSO:50 mg/mL (38.84 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (1.55 mM)

Bioactivity

• In Vivo:
  Female BALB/c mice were treated with Mogroside V (2.5, 5 and 10 mg/kg) for 1 h prior to intranasal injection of LPS (10 μg in 50 μl). After 12 h, airway inflammation in the ALI model was determined by the wet/dry weight (W/D) ratio, myeloperoxidase (MPO) activity of lung tissue, leukocyte recruitment and cytokine levels in the bronchoalveolar lavage fluid (BALF). Additionally, lung tissue was examined by histology and western blotting to investigate the changes in pathology and the signalling in the presence and absence of Mogroside V. Mogroside V at 5 and 10 mg/kg inhibited airway inflammation induced by LPS as measured by the decrease in the histological changes (44 and 67.3% reduction in lung injury score, respectively), a 28.9 and 55.3% reduction in lung MPO activity, and inflammatory cell counts, interleukin-1β (IL-1β, 382 and 280 pg/ml, respectively), IL-6 (378 and 232 pg/ml, respectively) and tumor necrosis factor-α (TNF-α, 12.5 and 7.8 ng/ml, respectively) levels in the BALF. Additionally, Mogroside V treatment reduced the activation of cyclooxygenase 2 (COX-2), inducible NO synthase (iNOS), and the nuclear factor (NF)-κB.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

AMPK, Mogroside V, inhibit, Inhibitor

Compound Identifiers

PubChem CID

24721270